ArticleEuropean journal of rheumatology2025
Uveitis in Psoriatic Arthritis: A Comprehensive Review.
Article in European journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dual-Site Inflammation During Adalimumab Therapy: Birdshot Chorioretinopathy Complicated by Paradoxical Psoriasis.Cureus · 2026Article
- Current and Emerging Therapies for Uveitis in Axial Spondyloarthritis: A Scoping Review.Mediterranean journal of rheumatology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriatic arthritis (PsA) belongs to the spectrum of spondyloarthritides, primarily affecting skin and joints. Apart from skin involvement, other extra-articular manifestations can coexist. Uveitis, although not very frequently encountered, is one of the most serious of them, necessitating prompt diagno- sis and proper treatment to prevent irreversible sight-threatening complications. Psoriatic arthritis related uveitis is usually unilateral, characterized by anterior segment inflammation, with the absence of redness or pain making it possible to miss the diagnosis. This review gives a comprehensive insight into the pathophysiology and clinical manifestations of PsA-related uveitis, along with an exposition of various epidemiologic features, as derived from relevant observational studies. Therapeutic approaches and available treatments are also reviewed. Although definitive recommendations on treatment seem rather challenging for PsA-related uveitis, tumor necrosis factor inhibitors appear to have the lead over other biologic therapies. A multi-disciplinary approach, tight screening, and disease activity control, as well as proper targeted therapy, remain pivotal.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.